Cyclophilin A (CypA), a member of the immunophilin family, is a ubiquitously expressed protein with peptidyl-prolyl isomerase (PPIase) activity that facilitates protein folding and trafficking. It plays critical roles in immune regulation, inflammation, and cellular signaling, and serves as a key target for immunosuppressive drugs like cyclosporine A. CypA antibodies are essential tools for detecting and studying this protein in various biological contexts.
These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and flow cytometry to investigate CypA's involvement in diseases like HIV infection (where it aids viral replication), cardiovascular disorders, and cancer. Both monoclonal and polyclonal CypA antibodies are available, typically generated in hosts like rabbits or mice using immunogenic peptide sequences or recombinant CypA protein. Validation parameters include specificity (confirmed via knockout/knockdown controls), cross-reactivity, and application compatibility.
Researchers rely on CypA antibodies to explore its interactions with signaling molecules (e.g., NF-κB, MAPK), its role in oxidative stress, and its potential as a biomarker. High-quality antibodies ensure reproducibility in studies linking CypA dysregulation to pathological mechanisms or therapeutic responses. Proper selection requires attention to epitope regions, host species, and validation data provided by suppliers.